DGAP-Adhoc: Epigenomics AG: planned capital reduction in the ratio 4:1 | news

DGAP-Ad-hoc: Epigenomics AG / Keywords: Corporate Action/General Meeting
Epigenomics AG: 4:1 capital reduction planned

09/09/2022 / 19:19 CET/CEST
Disclosure of internal information pursuant to Article 17 of Regulation (EU) No. 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer/publisher is responsible for the content of the message.

Epigenomics AG: 4:1 capital reduction planned

Berlin, 9 September 2022 Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the Company) plans to participate in the extraordinary general meeting to be convened on October 21, 2022, which will be held as a virtual general meeting without the presence of shareholders or their proxies, apart from the declaration of loss in pursuant to section 92, subsection 1 AktG, to propose a reduction of the share capital to a quarter of the existing share capital at the general meeting.

The capital reduction must take place in two stages. Initially, the share capital must be reduced by raising up to three own shares acquired free of charge, so that the share capital is a multiple of four. The company’s share capital is then reduced to a quarter by an ordinary capital reduction in accordance with §§ 222 et seq. AktG The ordinary capital reduction must be done by combining the company’s shares in a ratio of 4:1 and partly serves to cover losses, and the rest is attributed to the company’s capital resources.

The actual amount of the capital reductions depends on the size of the share capital at the time of the extraordinary general meeting on 21 October 2022, which in turn depends on whether and to what extent the holders of the convertible bonds issued by the company exercise their conversion rights in the conversion window at the beginning of October 2022 does. Based on the current share capital of EUR 16,357,482.00, the capital would be increased by a EUR 2.00 cancellation of shares to EUR 16,357,480.00 and then by a EUR 12,268,110.00 consolidation of shares to EUR 4,089, 007 reduced.

The complete agenda together with explanations and more detailed information on registration for the extraordinary general meeting can be found in the invitation, which is expected to be published in the Federal Gazette from September 14, 2022 and also at https://www.epigenomics. com/de/news-investor/ general meeting/ will be visible.

Epigenomics AG, Geneststrasse 5, 10829 Berlin
Tel. +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, E-mail: contact@epigenomics.com

investor relations
IR.on AG, Frederic Hilke, phone +49 221 9140 970, e-mail: ir@epigenomics.com

Cautionary note regarding forward-looking statements

This release expressly or implicitly contains forward-looking statements regarding Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that could cause the actual future results, financial condition and performance of Epigenomics AG to differ materially from the future results or performance expressed or implied by such statements. Epigenomics is publishing this announcement as of the date of this release and does not intend to update any of the forward-looking statements contained herein, whether as a result of new information, future events or otherwise.

09/09/2022 CET/CEST DGAP distribution services include legal reporting requirements, corporate news/financial news and press releases.
Media archive at http://www.dgap.de

Leave a Comment